NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I believe that any prediction for the price at the end of next year has to be based on assumptions about what happens next year. I believe the worst case is only achieving UK approval next year. The best case would include acceptance of the EDEN unit for commercial production and approval by the other three regulators in addition to new trials some of which are funded by others, and perhaps new partnerships. The point is, there are so many possibilities that could occur during the year that at the end of the year the share price could fall into a range as low as $4 to perhaps $25 or more if all that could happen during the year did happen. I would expect it to fall someplace in the middle, but anything is possible, including a buyout or partnership at substantially more if trials are indicating that DCVax-Direct is headed for approval and DCVax-L for a tumor agnostic label that quickly.

As we head into the power hour it's hard to tell which way we'll go, I would hope for a close that's up $.15 or more.

Gary